Compounds > canertinib
Page last updated: 2024-09-04

canertinib and sorafenib

canertinib has been researched along with sorafenib in 7 studies

Compound Research Comparison

Studies
(canertinib)		Trials
(canertinib)		Recent Studies (post-2010)
(canertinib)		Studies
(sorafenib)		Trials
(sorafenib)		Recent Studies (post-2010) (sorafenib)
1249656,5207305,251

Protein Interaction Comparison

ProteinTaxonomycanertinib (IC50)sorafenib (IC50)
Aurora kinase AHomo sapiens (human)3.8
Receptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)3.6
Bile salt export pumpHomo sapiens (human)8.6667
Tyrosine-protein kinase ABL1Homo sapiens (human)0.1
Tyrosine-protein kinase ABL1Mus musculus (house mouse)0.2259
Epidermal growth factor receptorHomo sapiens (human)0.2145
RAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)0.1333
Receptor tyrosine-protein kinase erbB-2Homo sapiens (human)0.131
Platelet-derived growth factor receptor betaMus musculus (house mouse)0.1235
Insulin receptorHomo sapiens (human)5.3
Tyrosine-protein kinase LckHomo sapiens (human)0.06
Macrophage colony-stimulating factor 1 receptorHomo sapiens (human)0.0385
Proto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)0.026
Hepatocyte growth factor receptorHomo sapiens (human)5.75
Tyrosine-protein kinase HCKHomo sapiens (human)0.53
Platelet-derived growth factor receptor betaHomo sapiens (human)0.1164
Serine/threonine-protein kinase A-RafHomo sapiens (human)0.0087
Mast/stem cell growth factor receptor KitHomo sapiens (human)0.1937
Fibroblast growth factor receptor 1Homo sapiens (human)0.2827
AromataseHomo sapiens (human)0.1269
Proto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)0.39
Serine/threonine-protein kinase B-rafHomo sapiens (human)0.3699
Platelet-derived growth factor receptor alphaHomo sapiens (human)0.427
Vascular endothelial growth factor receptor 1 Homo sapiens (human)0.06
Cyclin-CHomo sapiens (human)0.0663
Mitogen-activated protein kinase 3 Homo sapiens (human)0.0181
Serine/threonine-protein kinase B-raf Mus musculus (house mouse)0.13
Mitogen-activated protein kinase 1Homo sapiens (human)0.1095
Sodium-dependent serotonin transporterRattus norvegicus (Norway rat)0.0011
Bifunctional epoxide hydrolase 2Homo sapiens (human)0.012
Vascular endothelial growth factor receptor 3Homo sapiens (human)0.0191
Vascular endothelial growth factor receptor 3Mus musculus (house mouse)0.1269
Vascular endothelial growth factor receptor 2Mus musculus (house mouse)0.1129
Vascular endothelial growth factor receptor 2Homo sapiens (human)0.1
Receptor-type tyrosine-protein kinase FLT3Homo sapiens (human)0.0348
Casein kinase I isoform alphaHomo sapiens (human)0.25
Cyclin-dependent kinase 8Homo sapiens (human)1.1294
Glycogen synthase kinase-3 betaHomo sapiens (human)5.77
Ephrin type-B receptor 4Homo sapiens (human)0.5442
Fatty-acid amide hydrolase 1Rattus norvegicus (Norway rat)6.1
Cyclin-dependent kinase 6Homo sapiens (human)0.13
Dual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)3.3
Angiopoietin-1 receptorHomo sapiens (human)0.0032
Tyrosine-protein kinase MerHomo sapiens (human)1.37
Receptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)1.5
Mitogen-activated protein kinase 14Homo sapiens (human)0.6228
Discoidin domain-containing receptor 2Homo sapiens (human)0.0215
Serine/threonine-protein kinase TNNI3KHomo sapiens (human)0.175
Vascular endothelial growth factor receptor 2Danio rerio (zebrafish)2.6
Homeodomain-interacting protein kinase 1Homo sapiens (human)0.1
Homeodomain-interacting protein kinase 4Homo sapiens (human)0.0515
Cyclin-dependent kinase 19Homo sapiens (human)0.206
Homeodomain-interacting protein kinase 2Homo sapiens (human)0.1
Homeodomain-interacting protein kinase 3Homo sapiens (human)0.1
MAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)0.262
Broad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)3.1

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (28.57)29.6817
2010's4 (57.14)24.3611
2020's1 (14.29)2.80

Authors

AuthorsStudies
Atteridge, CE; Azimioara, MD; Benedetti, MG; Biggs, WH; Carter, TA; Ciceri, P; Edeen, PT; Fabian, MA; Floyd, M; Ford, JM; Galvin, M; Gerlach, JL; Grotzfeld, RM; Herrgard, S; Insko, DE; Insko, MA; Lai, AG; Lélias, JM; Lockhart, DJ; Mehta, SA; Milanov, ZV; Patel, HK; Treiber, DK; Velasco, AM; Wodicka, LM; Zarrinkar, PP1
Atteridge, CE; Campbell, BT; Chan, KW; Ciceri, P; Davis, MI; Edeen, PT; Faraoni, R; Floyd, M; Gallant, P; Herrgard, S; Hunt, JP; Karaman, MW; Lockhart, DJ; Milanov, ZV; Morrison, MJ; Pallares, G; Patel, HK; Pritchard, S; Treiber, DK; Wodicka, LM; Zarrinkar, PP1
Ciceri, P; Davis, MI; Herrgard, S; Hocker, M; Hunt, JP; Pallares, G; Treiber, DK; Wodicka, LM; Zarrinkar, PP1
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ1
Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP1
Guo, Y; He, J; Li, Y; Liu, M; Liu, Y; Xiao, J; Yu, W; Zhang, Q1
Bharate, SB; Raghuvanshi, R1

Reviews

1 review(s) available for canertinib and sorafenib

ArticleYear
The association between anti-tumor potency and structure-activity of protein-kinases inhibitors based on quinazoline molecular skeleton.
    Bioorganic & medicinal chemistry, 2019, 02-01, Volume: 27, Issue:3

    Topics: Animals; Antineoplastic Agents; Cell Proliferation; Humans; Neoplasms; Protein Kinase Inhibitors; Protein Kinases; Quinazolines

2019

Other Studies

6 other study(ies) available for canertinib and sorafenib

ArticleYear
A small molecule-kinase interaction map for clinical kinase inhibitors.
    Nature biotechnology, 2005, Volume: 23, Issue:3

    Topics: Benzamides; Drug Design; Escherichia coli; Escherichia coli Proteins; Imatinib Mesylate; Microchemistry; Pharmaceutical Preparations; Piperazines; Protein Binding; Protein Interaction Mapping; Protein Kinase Inhibitors; Pyrimidines

2005
A quantitative analysis of kinase inhibitor selectivity.
    Nature biotechnology, 2008, Volume: 26, Issue:1

    Topics: Binding Sites; Enzyme Activation; Humans; Phosphotransferases; Protein Binding; Protein Interaction Mapping; Protein Kinase Inhibitors; Proteome; Quantitative Structure-Activity Relationship

2008
Comprehensive analysis of kinase inhibitor selectivity.
    Nature biotechnology, 2011, Oct-30, Volume: 29, Issue:11

    Topics: Catalysis; Drug Design; Enzyme Stability; High-Throughput Screening Assays; Humans; Protein Binding; Protein Kinase Inhibitors; Protein Kinases; Proteomics; Signal Transduction; Substrate Specificity

2011
Identification of potent Yes1 kinase inhibitors using a library screening approach.
    Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15

    Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship

2013
The target landscape of clinical kinase drugs.
    Science (New York, N.Y.), 2017, 12-01, Volume: 358, Issue:6367

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays

2017
Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
    Journal of medicinal chemistry, 2022, 01-27, Volume: 65, Issue:2

    Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Drug Approval; Drug Repositioning; High-Throughput Screening Assays; Humans; Protein Kinase Inhibitors; SARS-CoV-2; United States; United States Food and Drug Administration; Virus Diseases

2022